Loading quotes...

Forecast

The analysts' average price target is €58.90 (-9.54%). The median is €65.36 (+0.38%).

Buy	12
Hold	14
Sell	0

News Go to news feed

Shareholder lawsuit forces Bio-Techne to provide additional disclosures on Merck merger

Bio-Techne issued supplemental information to the proxy materials for its planned merger with Merck KGaA after a shareholder lawsuit filed on Sept. 9 and several demand letters. The suit alleges that material information was omitted or misrepresented in the proxy statement and seeks a court order blocking the shareholder vote scheduled for Sept. 23. Bio-Techne says the allegations are unfounded but has voluntarily provided extra details, including on prior takeover talks, the terms of Goldman Sachs’s engagement and updated financial metrics to enable the vote. The company also reported Q4 revenue of $321.2 million, beating expectations, with slightly lower adjusted EPS of $0.52; the merger would make Bio-Techne a wholly owned subsidiary of Merck, subject to approvals. » More on de.investing.com
Bio-Techne rises to 52-week high at $72.39

Bio-Techne’s shares reached a 52-week high of $72.39, giving the company a market capitalization of $11.27 billion; year-to-date the gain is 23% and the stock is up 34.94% over the past year. InvestingPro rates the stock as overvalued relative to its fair value. For the fourth quarter of fiscal 2026, Bio-Techne reported adjusted EPS of $0.52 (meeting analyst consensus) and revenue of $321.2 million, beating the $314.7 million estimate; organic growth was 3%. Bio-Techne is also in the process of being acquired by Merck KGaA, Darmstadt, Germany. » More on de.investing.com
Bio-Techne announces quarterly dividend of $0.08

The board of directors of Bio-Techne has declared a quarterly dividend of $0.08 per share for the quarter ending June 30, 2026. The dividend will be paid on August 28, 2026 to shareholders of record on August 17, 2026. Management will review future cash dividends on a quarterly basis; Bio-Techne reported net revenue of more than $1.2 billion for fiscal 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Bio-Techne Corp has already paid €0.21 in dividends. The last payout was in September.

Financials

In the last quarter, Bio-Techne Corp had revenue of €281.43M and net profit of €47.85M

(EUR)	June 2026	YoY
Revenue	281.43M	4.65%
Gross profit	185.23M	9.81%
Net profit	47.85M	419.04%
EBITDA	80.52M	1,376.04%

Fundamentals

Metric	Value
Market capitalization	€10.2B
Number of shares	156.82M
52-week high/low	€65.14 - €38.68
Dividend yield	0.42%
Dividends TTM	€0.27
Beta	1.30
P/E ratio	62.10
PEG ratio	0.40
P/B ratio	5.38
P/S ratio	9.38

Company profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Name	Bio-Techne Corp
CEO	Kim Kelderman
Headquarters	Minneapolis, mn USA
Website	bio-techne.com
Sector	Health Care
Industry	Health Care Technology
IPO	02/09/1989
Employees	3,000